Valiant Laboratories Limited

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming that all securities are held in dematerialized form and no requests for dematerialization, mutilation, or cancellation were received during the quarter ended September 30, 2026.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Valiant Laboratories Limited

Valiant Laboratories Limited has submitted the Srutinizers report of its Annual General Meeting held on September 28, 2026, and informed the Exchange about the voting results.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 28, 2026.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange about its proposed acquisition of shares in AMPYR Renewable Energy Resources Twelve A Private Limited for an aggregate consideration not exceeding ₹70,00,000. The investment is proposed to be made to participate in a group captive open access arrangement under the Electricity Act, 2003.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the members of the Company.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange about the credit rating assigned by India Ratings and Research (Ind-Ra) to the company's bank loan facilities.

Valiant Laboratories Limited

Valiant Laboratories Limited has dispatched letters to shareholders who had not registered their email addresses, informing them about the Annual Report for the Financial Year 2025-26 and the Notice of the 5th Annual General Meeting.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026 and the Annual Report for the FY 2025-26.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. 5th AGM of the Company.

Valiant Laboratories Limited

Valiant Laboratories Limited has published its standalone and consolidated audited financial results for the quarter ended June 30, 2026, with a net profit of ₹94,788 and a total income from operations of ₹74,273.7 crore.

Valiant Laboratories Limited

Valiant Laboratories Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of funds raised through a Rights Issue. The report, issued by India Ratings and Research Private Limited, states that there has been no deviation from the objects of the issue.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding change in Corporate Office of the company. The Board of Directors has approved the re-appointment of Managing Director, re-appointment of Independent Director, continuation of directorship of Non-Executive Non-Independent Director, shifting of Registered Office, opening of a new Corporate Office, and additional investment in Valiant Advanced Sciences Private Limited.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding change in Registered Office of the company, along with other corporate updates.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange about the re-appointment of its Managing Director, Mr. Santosh Vora, and Independent Director, Mrs. Sonal Vira, and the continuation of directorship of Mr. Shantilal Vora. The company has also approved the opening of a new Corporate Office and the shifting of its Registered Office. Additionally, the Board has approved an investment of up to Rs. 60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, through the subscription of Optionally Convertible Redeemable Preference Shares.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company. The Board of Directors has approved the re-appointment of Mr. Santosh Vora as the Managing Director for a further period of five (5) years, and the re-appointment of Mrs. Sonal Vira as an Independent Director for a second term. Additionally, the Board has approved the continuation of directorship of Mr. Shantilal Vora as a Non-Executive Non-Independent Director upon his attaining the age of 75 years.

Valiant Laboratories Limited

Valiant Laboratories Limited has announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results and taking on record the audit report issued by Raman S. Shah & Co., Chartered Accountants.

Valiant Laboratories Limited

Valiant Laboratories Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming that no dematerialization, mutilation, or cancellation of securities was received during the quarter ended June 30, 2026.

Valiant Laboratories Limited

Valiant Laboratories Limited has informed the Exchange regarding the closure of the trading window for its directors, promoters, and other connected persons due to the declaration of financial results for the quarter ended June 30, 2026.

Valiant Laboratories Limited

Valiant Laboratories Limited responds to a clarification sought by the National Stock Exchange of India regarding its financial results for the quarter and year ended March 31, 2025. The company clarifies that its independent auditor's report inadvertently missed a note relating to the balancing figure, as required under the format prescribed by SEBI. The auditor has issued a clarification stating that the financial results include the result for the quarter ended March 31, 2025, being the balancing figure between the audited figures in respect of the full financial year and the published audited year-to-date figure up to the third quarter of the current financial year.